USFDA gives nod to Ajanta Pharma for Asthma treatment

Published On 2015-08-05 07:40 GMT   |   Update On 2015-08-05 07:40 GMT
Advertisement
Drug firm Ajanta Pharma will now market the generic montelukast tablets and oral granules used for prevention and treatment of asthma and to relieve symptoms of seasonal hay fever

Drug firm Ajanta Pharma has received the green signal from US Food and Drug Administration for its three abbreviated new drug applications (ANDAs). The final approval comes for the montelukast tablets, montelukast sodium chewable tablets and montelukast granules, used for used for prevention and treatment of asthma and to relieve symptoms of seasonal hay fever.
Advertisement

The approval for montelukast tablets in the strength of 10 mg, montelukast sodium chewable tablets have received nod for strengths of 4mg and 5 mg, respectively.

"For 12 months ending June 2015, montelukast tablets, chewable tablets and granules had sales of approximately USD 237 million, USD 87 million and USD 31 million respectively, according to IMS health," Ajanta Pharma said.

The company plans to launch the generic products shortly, it added.

 
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News